FDA Adverse Event Injury Summary report: N

ENDURANT STENT GRAFT SYSTEM

MDR report key: 2190818 · Received July 8, 2011

Report

Report Number
2953200-2011-01261
Event Type
Injury
Date Received
July 8, 2011
Date of Event
June 9, 2011
Report Date
June 9, 2011
Manufacturer
MEDTRONIC CARDIOVASCULAR IRELAND
Product Code
MIH
PMA / PMN Number
P100021
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
KS, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). EVALUATION, RESULTS: (ARTERIAL VESSEL OCCLUSION); (UNKNOWN CAUSE OF EVENT). CONCLUSIONS: (UNKNOWN CAUSE OF EVENT).

Description of Event or Problem · 1

AN ANEURX STENT GRAFT SYSTEM (REF MFR 2953200-2011-01029) WAS IMPLANTED IN A PT FOR THE ENDOVASCULAR TREATMENT OF AN ABDOMINAL AORTIC ANEURYSM APPROX SIX YEARS AGO. THE ANEURYSM DIAMETER AT THE TIME OF IMPLANT WAS NOT REPORTED. THE VESSEL MORPHOLOGY WAS REPORTED AS THE AORTIC NECK WAS 2.5 CM TO 3 CM IN LENGTH AND THE ILIAC LIMBS WERE NARROW IN DIAMETER. THE STENT GRAFTS WERE SUCCESSFULLY IMPLANTED IN THE PT. A CT SCAN 10 WEEKS AGO DEMONSTRATED THAT THE ANEURYSM MEASURED 5.6 CM ANTERIOR TO POSTERIOR X 5.8 CM TRANSVERSELY. THERE WAS CONTRAST ALONG THE UPPER MARGIN OF THE STENT GRAFT, CONSISTENT WITH A PROXIMAL TYPE I ENDOLEAK. THE PT WAS SUCCESSFULLY TREATED WITH A 28 MM ANEURX CUFF AND A 36 MM ENDURANT CUFF AND THIS RESOLVED THE ENDOLEAK. ON A CT SCAN TAKEN ONE MONTH AGO, THE ENDURANT CUFF (REF MFR 2953200-2011-01261), WHICH WAS PLACED AS THE MOST PROXIMAL GRAFT, WAS SEEN TO HAVE 75% COVERAGE OF THE RIGHT RENAL (LOWEST RENAL) AND 25% OF THE LEFT RENAL. AT IMPLANT, NO COVERAGE WAS NOTED; THE CAUSE OF THE EVENT IS UNK. THERE WAS AN ELEVATED CREATININE. A RENAL BYPASS WAS PERFORMED WITHOUT ISSUES. NO ADDITIONAL CLINICAL SEQUELAE WERE REPORTED AND THE PT IS FINE POST BYPASS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ENDURANT STENT GRAFT SYSTEM MIH MEDTRONIC CARDIOVASCULAR IRELAND NA V00853940

Patients

Seq Age Sex Outcome Treatment
1 63 YR Required Intervention